Physician profile
David B Smith
NPI 1821036161
$9,041.51
in general payments reported to CMS, 2019-2025
30 companies · $2,131 in 2025
The $2,131 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,069 · 2022: $1,989 · 2023: $1,810 · 2024: $2,042 · 2025: $2,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,983.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,848.74 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,763.94 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $1,391.36 | 2021-2025 | |
| Mylan Specialty L.P. | $511.04 | 2021-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $388.61 | 2021-2025 | Acthar |
| Philips North America LLC | $356.44 | 2021-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Amgen INC. | $341.76 | 2021-2025 | Tezspire |
| United Therapeutics Corporation | $320.18 | 2022-2025 | Tyvaso, Tyvaso |
| Inspire Medical Systems, INC. | $278.72 | 2023-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $276.58 | 2022-2025 | Dupixent |
| Insmed, INC. | $269.17 | 2024-2025 | Arikayce, Brinsupri |
| Ani Pharmaceuticals, INC. | $239.48 | 2022-2025 | Purified Cortrophin Gel |
| Viatris Specialty LLC | $172.88 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.67 | 2021-2025 | Ofev, Jascayd |
| Actelion Pharmaceuticals US, INC. | $93.33 | 2021-2025 | Uptravi, Opsumit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $82.10 | 2021-2023 | Glassia |
| Advanced Respiratory, INC | $81.38 | 2021 | |
| Verona Pharma, INC. | $70.56 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $63.19 | 2022-2025 | Xolair |
| Harmony Biosciences LLC | $60.01 | 2024 | |
| Novartis Pharmaceuticals Corporation | $52.13 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $49.34 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.67 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $41.00 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $25.28 | 2021 | |
| Electromed, INC. | $16.49 | 2025 | Smartvest |
| Uswm, LLC | $16.15 | 2021 | |
| Axsome Therapeutics, INC. | $15.87 | 2024 | Sunosi |
| Pharming Healthcare, INC. | $14.28 | 2023 | Ruconest |
| Vanda Pharmaceuticals INC. | $14.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.